0.350
0.02 (4.67%)
| Penutupan Terdahulu | 0.334 |
| Jumlah Dagangan | 3,852 |
| Harga / Buku (P/B) | 0.300 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.780 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 56.38% |
| Nisbah Semasa (MRQ) | 0.540 |
| Aliran Tunai Operasi (OCF TTM) | -30.01 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -18.54 M |
| Pulangan Atas Aset (ROA TTM) | -178.72% |
| Pulangan Atas Ekuiti (ROE TTM) | -916.17% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Reviva Pharmaceuticals Holdings | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.2 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -3.0 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -1.00 |
|
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer’s disease and Parkinson’s disease psychosis and its other drug candidate is RP1208. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.30% |
| % Dimiliki oleh Institusi | 20.35% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |